Cellular Responses to Anticancer Drugs

• 2924 · PDF ζ-Stat inhibits glioblastoma multiforme progression by targeting PKC-ζ/Cx43 signaling and inducing senescence Grazielly Teodoro, Shreejana Rimal, Wishrawana S. Ratnayake, Abigail Olatunji, Mildred Acevedo-Duncan
• 2925 · PDF Monzosertib, a selective CDC7 inhibitor, induces cell death via premature mitosis promoted by the FOXM1-cyclinB1 axis Hiroko Endo, Yu Nishioka, Mariko Hatakeyama, Youichi Tajima, Sayuri Ito, Akinori Arimura, Hisao Masai, Masaaki Sawa
• 2926 · PDF Sonrotoclax (BGB-11417), a selective Bcl-2 inhibitor, demonstrates better efficacy than Venetoclax (Ven) and Lisaftoclax (APG-2575) in hematological cancer cells, xenografts, and human bloods Haitao Wang, Lin Li, Yiwen Wang, Hao Wang, Weiwei Song, Shuang Peng, Sijia Zhai, Ziyu Jia, Peng Chi, Xiaoyu Feng, Teiko Sumiyoshi, Wei Jin, Zhirong Shen
• 2927 · PDF Synthetic lethality of G6PD deficiency and asparaginase for colorectal cancer therapy Yun-Cheol Chae, Alan Wong, Su Hyun Lee, Anais Barthe, Meaghan McGuinness, Samantha Fitzgerald, Sima Jeha, Seth Karol, Kimmie Ng, Marios Giannakis, Naama Kanarek, Alejandro Gutierrez
• 2928 · PDF KRAS inhibition-induced GSDME-mediated pyroptosis and its augmentation by LAT1 inhibition in KRAS-mutant lung cancer Kenji Morimoto, Ju Hwan Cho, Po-Lan Su, Peiran Xu, Andrew Barnes, Rahul Shivahare, Jacob Kaufman, Zihai Li, David Paul Carbone, Kai He
• 2929 · PDF Immune and pharmacodynamic effects of sotorasib plus panitumumab in KRAS G12C-mutant colorectal cancer: Paired biopsy results from CodeBreaK 101 David Hong, Lata Mukundan, Abraham Anderson, Emily Chan, Dorothy French, Linnea Haeggblom, Daniel Lu, Toshiki Masuishi, Rona Yaeger, Yuliya Katlinskaya
• 2930 · PDF Unraveling determinants of drug response: PRISM viability profiling of hundreds of oncology therapeutics reveals mediators of selectivity and mechanism Matthew G. Rees, Mustafa Kocak, Matthew J. Emmett, Colleen T. Harrington, Li Wang, Anthony Fazio, Alvin Kalathungal, Dennie T. Frederick, Aydin Golabi, Rachael Barry, Emily Reeves, John Davis, Melissa M. Ronan, Laura Doherty, Jillian N. Eskra, William R. Sellers, Jennifer A. Roth
• 2931 · PDF RC108, a c-Met-targeting ADC, exhibits differential cytotoxicity between cMet-high and HGF-dependent tumor cells compared with Teliso-V, suggesting a potential safety advantage Jiayue Geng, Zhanjiao Yu, Haiqing Zhong, Qingbo Wang, Xiao Lv, Tongyu Xiao, Kailin Wang, Xiaoping Zhang, Xiaoli He, Lili Wang, Ying Jiang, Jianing Liu, Yinghao Xin, Jianmin Fang, Yuanhao Li
• 2932 · PDF Combination of miRNA-379-5p and miRNA-125a-3p for the treatment of platinum resistant ovarian cancer Serenade Trevino, Trey Zepeda, Sue Anne Chew
• 2933 · PDF Itareparib: A potent, selective and non-trapper PARP1 inhibitor for combination therapy with DNA damaging agents in solid tumors Alessandro Galbiati, Gianluca Papeo, Nilla Avanzi, Fabio Gasparri, Claudia Perrera, Gemma Texido, Lisa Mahnke, Shiho Nakano, Kang Jin Jeong, Gordon B. Mills, Junko Murai, Alessia Montagnoli
• 2934 2934 Characterizing response to PARP inhibitor treatment combinations in advanced prostate cancer Bryan Correa Gonzalez, Akshaya Karthikeyan, Love A. Moore, Ethan Sandoval, Anamitra Bhuamik, Marion Hardy, Alan P. Lombard
• 2935 · PDF Establishment of experimental model for measuring antibody-drug conjugate (ADC) bystander effects in breast cancer Hyunmyoung Yun, Won-Ji Ryu, Hyein Jung, Tae Yeong Kim, Cheol-Hwa Hong, Yumi Hwang, Hyun Ju Han, Geon-Uk Kim, Seo Young Lee, Kyoo Hyun Kim, Min Hwan Kim, Gun Min Kim, Joo Hyuk Sohn
• 2936 · PDF NAMPT inhibition enhances the efficacy of standard chemotherapies and immunomodulation in pancreatic ductal adenocarcinoma Purnachandra Nagaraju Ganji, Sujith Sarvesh, Dhana Sekhar Reddy Bandi, Husain Yar Khan, Irfana Muqbil, Amro Aboukameel, Sahar Bannoura, Khalil Choucair, Walid Sukkari, Sunil Jaiman, Rafic Beydoun, Gergory Dyson, Yang Shi, N. Vaishampayan, Eliza W. Bael, Miguel Tobon, Steve Kim, Herbert Chen, Muhammad W. Saif, Anthony Frank Shields, Philip A. Philip, Min Wu, Michael Schelle, Boris Pasche, Asfar S. Azmi, Bassel F. El-Rayes
• 2937 · PDF Imipridones ONC201, ONC206, and ONC212 show potent killing and colony arrest of small-cell lung cancer cell lines Audrey Y. Su, Connor Purcell, Shengliang Zhang, Lanlan Zhou, Ashley S. Uruchurtu, Wafik S. El-Deiry
• 2938 · PDF KRAS and ERK5 signaling pathways in cancer: Implications for targeted therapy Christophe Marcireau, Fréderic Lacroix, Fatima Amor, Karine Dobrazix, Guillaume Nurit, Véronique Jean-Baptiste, Eiwen Yang, Donald Jackson, Colette Dib, Gaelle Muzard, Franck Slowinski, Laurent Debussche, Pawel K. Mazur
• 2939 2939 Extrachromosomal DNA plasticity enables novel trajectories of cancer adaptation to drug treatments Jingting Chen, Joseph M. Dahl, Poorya Behnamie, Elizabeth Brunk
• 2940 · PDF Tumor-selective dimeric and monomeric RAF targeting with a next-generation Type 1 RAF inhibitor Mathieu Desaunay, Tara L. Peters, Evangelia Matenoglou, Beau Baars, Bijaya Gaire, Ana Orive-Ramos, Li Ren, Joseph P. Lyssikatos, Michael R. Burkard, Dalton Dacus, Matthew J. Sale, Stuart A. Aaronson, Frank McCormick, Evripidis Gavathiotis, Stefan D. Gross, Poulikos I. Poulikakos
• 2941 · PDF Pharmacologic ascorbate exerts anticancer activity through ROS-dependent metabolic vulnerability in MYCN-amplified neuroblastoma Tasfia Farah, Qi Chen
• 2942 · PDF Inhibition of stearoyl-CoA desaturase 1 (SCD1) by SSI-4 as a therapeutic strategy in non-small cell lung cancer Valeria Romina Salerno Gonzales, Lauren Antal, Tamiel Nichole Turley, John A. Copland III
• 2943 · PDF Antitumor effect of TROP2-targeted antibody drug conjugate, datopotamab deruxtecan (Dato-DXd), in association with DNA damage response in breast cancer cell lines Seohyeon Lim, Sujin Ham, Hae Min Hwang, Youlim Noh, Jiwon Koh, Chaeyoung Lee, Minyoung Jeong, Yu-Jin Kim, Minyoung Lee, Sohyeon Kim, Changhee Park, Dae-Won Lee, Kyung-Hun Lee, Seock-Ah Im
• 2944 · PDF Uncovering the zinc-dependent pathways of response and resistance to THZ1 in clear cell ovarian cancer Maya Modak, Soledad Ochoa, Forough Abbasi, Dandi Huang, Robbin Nameki, BJ Rimel, Kate Lawrenson
• 2945 · PDF Target actin-microtubule network integrity to enhance taxane drug-target engagement and chemosensitivity in prostate cancer Felipe Carvolho, Tanvi Desai, Keira Ly, Joubin Jebelli, Ajay Bommareddy, Jianning Wei, Michael L. Lu
• 2946 · PDF RQ43: A quinoline derivative that inhibits pancreatic cancer cell EMT and migration Sreyoshi Das, Qi Chen
• 2947 2947 Inhibition of NRF2 driven antioxidant defence and EMT underlies brusatol induced cytotoxicity in cervical cancer cells Gunjan Dagar, Mohd Umar Rehmani, Teena Haritwal, Ajaz A. Bhat, Mayank Singh
• 2948 · PDF A spatial-trapping mechanism of RAF by RAF/MEK glue enables full-dose combination with a pan-RAF inhibitor and drives potent, RAS-mutant tumor-selective MAPK and growth inhibition Bijaya Gaire, Ana Orive-Ramos, Christos Adamopoulos, Beau Baars, Mathieu Desaunay, Evangelia Matenoglou, Silvia Coma, Nayeli Gutierrez-Trejo, Kevin Mohammed, Stuart A. Aaronson, Jian Jin, Tiphaine Martin, Ernesto Guccione, Evripidis Gavathiotis, Jonathan A. Pachter, Poulikos I. Poulikakos
• 2949 · PDF Palazestrant, a CERAN, in combination with OP-3136, a KAT6 inhibitor, synergistically downregulates cell proliferation and metastasis related gene signatures Susanna A. Barratt, Gopinath S. Palanisamy, Azita Ghodssi, Chelsea Hope, Guadelupe Peña, Srinivasan Jayaraman, Raymond A. Ng, David C. Myles
• 2950 · PDF Palazestrant directly recruits the corepressor protein NCoR1 in vitro leading to complete antagonism of estrogen receptor alpha Susanna A. Barratt, Guadelupe Peña, Chelsea Hope, Gopinath S. Palanisamy, Raymond A. Ng, David C. Myles
• 2951 · PDF Adaptive and acquired mechanisms underlying RAS-mutant tumor response to mutant and state selective RAS inhibitors Ziyue Kou, Bijaya Gaire, Beau Baars, Mathieu Desaunay, Poulikos I. Poulikakos

在会议检索中浏览本分会场